Outcomes of Curative-Intent Endoscopic Resection Combined With Adjuvant Immune Checkpoint Inhibition for Resectable Sinonasal Mucosal Melanoma.

Authors

Teru Ebihara, Soichiro Fukuzato, Kazuhiro Omura, Naohiro Takeshita, Yuma Waki, Yoshimasa Nobeyama, Midoriko Morikawa, Masao Kobayashi, Tetsuo Akimoto, Nobuyoshi Otori

Published in

Head & neck. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

Evidence for adjuvant immune checkpoint inhibitor (ICI) therapy after curative-intent resection of sinonasal mucosal melanoma (SNMM) is limited.
We retrospectively reviewed 11 patients with resectable N0M0 SNMM who underwent curative-intent endoscopic resection followed by adjuvant ICI. Outcomes and immune-related adverse events (irAEs) were summarized descriptively, and univariable Cox proportional hazards regression was performed as an exploratory analysis to explore potential risk factors.
The 1- and 3-year overall survival rates were 100.0% and 90.0%; recurrence-free survival rates were 45.5% and 0%. Any-grade and grade ≥ 3 irAEs occurred in 8 of 11 patients (72.7%) and 3 patients (27.3%). T4a disease was associated with shorter recurrence-free survival than T3 disease (hazard ratio, 13.96; 95% confidence interval, 1.24-157.50; p = 0.033).
Recurrence was frequent and early, whereas overall survival remained preserved. Although efficacy cannot be inferred without a comparator, these data support multicenter evaluation of treatment sequencing and risk stratification.

PMID:
42702508
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.